Multiple Myeloma: Treatment Challenges and Updates

Multiple Myeloma: Treatment Challenges and Updates

On-Demand Webcast
Faculty

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

James R. Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California

Ajai Chari, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Adam D. Cohen, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennslyvania

Angela Dispenzieri, MD
Mayo Clinic
Rochester, Minnesota

Rafael Fonseca, MD
Mayo Clinic
Phoenix, Arizona

Jens Hillengass, MD
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Shaji K. Kumar, MD
Mayo Clinic
Rochester, Minnesota

C. Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

Deepu Madduri, MD
Mount Sinai Hospital
New York, New York

Sham Mailankody, MBBS
Memorial Sloan Kettering Cancer Center
New York, New York

Joseph R. Mikhael, MD, MEd, FRCPC
City of Hope Cancer Center
Translational Genomics Research Institute
Phoenix, Arizona

Gareth J. Morgan, MD
New York University School of Medicine
New York, New York

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota

Adriana Rossi, MD
Weill Cornell Medicine
New York, New York

Target Audience

This activity is intended for hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.

Overview

Multiple myeloma (MM) is a difficult and frustrating disease for both providers and patients. Clinicians are confronted with a large field of possible treatment combinations, and must consider varying mechanisms of action, toxicity profiles, clinical implications, and patient factors when selecting and sequencing treatment. However, although drug sequencing in MM is crucial for patient survival, there are no definitive recommendations concerning this vital treatment component. In addition, clinical trial efficacy outcomes are not representative of real-world survival rates due to a number of important factors. Lastly, drug resistance remains the biggest hurdle that clinicians must overcome for effective MM management. A host of novel and emerging agents are poised to address this issue, but clinicians will need a thorough knowledge of their pharmacological profiles and potential treatment placement in order to optimally integrate these agents into clinical practice.

This webcast aims to close the knowledge gap so that healthcare providers are positioned to effect meaningful change within the management of MM and positively impact patient care.

Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Describe the pharmacological action of new and emerging agents for MM treatment, including their potential role in treatment regimens
  2. Evaluate strategies for MM treatment selection and sequencing in both frontline and refractory/relapsed settings
  3. Examine factors driving the discrepancy between real-world effectiveness of MM agents and clinical trial efficacy outcomes

Release Date: December 20, 2019

Expiration Date: December 20, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Support

Supported by an educational grant from: Oncopeptides, Inc.

Accreditation

 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

PHYSICIANS

NACCME designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 5.25 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 5.25 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 5.25 contact hours.

CPE

This knowledge-based activity (JA0006201-9999-20-040-H01-P) is approved for 5.25 contact hours (0.525 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Kenneth C. Anderson, MD, David E. Avigan, MD, James R. Berenson, MD, Ajai Chari, MD, Adam D. Cohen, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Jens Hillengass, MD, Shaji K. Kumar, MD, C. Ola Landgren, MD, PhD, Suzanne Lentzsch, MD, PhD, Deepu Madduri, MD, Sham Mailankody, MBBS, Joseph R. Mikhael, MD, MEd, FRCPC, Gareth J. Morgan, MD, S. Vincent Rajkumar, MD, Adriana Rossi, MD; and Chris Bolwell, Lara Gray, and Griselda Zuccarino-Catania Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Kenneth C. Anderson, MD, reports that he is a consultant for Bristol-Myers Squibb, C4 Therapeutics, Celgene, Gilead, Janssen, Milennium-Takeda, OncoPep, Precision Biosciences Scientific, and Sanofi-Aventis.

James R. Berenson, MD, reports that he is a consultant for James R. Berenson MD Inc.; has received grant or research support from IMBCR; and is a speaker for James R. Berenson MD Inc.

Ajai Chari, MD, reports that she is a consultant for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Millenium/Takeda; has received grant or research support from Amgen, Array Biopharma, Celgene, Glaxo Smith Klein, Janssen, Millenium/Takeda, Novartis Pharmaceuticals, Oncoceutics, Pharmacyclics, and Seattle Genetics; and has has received other financial support from Amgen, Celgene, Janssen, Karyopharm, Millenium/Takeda, Sanofi, and Seattle Genetics.

Adam D. Cohen, MD, reports that he is a consultant for Celgene, GlaxoSmithKline, Janssen, Kite Pharma, Oncopeptides, Seattle Genetics, and Takeda; has received grant or research support from Novartis; and has received other financial support from Novartis.

Angela Dispenzieri, MD, reports that she has nothing to disclose in relation to this activity.

Rafeal Fornseca, MD, reports that he is a consultant for AbbVie, Aduro, Amgen, Bayer, BMS, Celgene, Janssen, Juno, Kite, Merck, Novartis, Pharmacyclics, Sanofi, and Takeda; and has received other financial support from Adaptive Biotechnologies.

Jens Hilengass, MD, reports that he is a consultant for Amgen and Janssen Biotech; and has received other financial support from Xian Janssen.

Shaji K. Kumar, MD, reports that he is a consultant for Abbvie, Adaptive, Amgen, Celgene, Genentech, Janssen, KITE, Merck, Medimmune, and Takeda; and has received grant or research support from Abbvie, Amgen, BMS, Celgene, Janssen, KITE, Medimmune, Merck, Novartis, Roche-Genentech, Sanofi, and Takeda.

C. Ola Landgren, MD, PhD, reports that he is a consultant for Amgen, BMS, Celgene, IDMC, Janssen, Merck, Sanofi, Takeda, and Theradex; and has received grant or research support from FDA, IMF, LLS, MMRF, NIH, Rising Tides, and Perlman Foundation.

Deepu Madduri, MD, reports that she is a consultant for Abbvie, Celgene, Janssen, and Takeda.

Sham Mailankody, MBBS, has received grant or research support from Celgene, Janssen, and Takeda.

Joseph R. Mikhael, MD, MEd, FRCP, reports that he is a consultant for Amgen, Celgene, Janssen, Karyopharm, Sanofi, and Takeda.

Gareth J. Morgan, MD, reports that he has nothing to disclose in relation to this activity.

S. Vincent Rajkumar, MD, reports that he has nothing to disclose in relation to this activity.

Adriana Rossi, MD, reports that she is a consultant for Amgen, Celgene, Janssen, and Sanofi; and has received grant or research support from BMS.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

Lara Gray disclosed no relevant financial relationships with any commercial interests.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.